BIM
LAB icon

Bogle Investment Management’s Standard BioTools LAB Stock Holding History

Bogle Investment Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-49,200
Closed -$295K – 59
2020
Q4 		$295K Buy
+49,200
New +$323K 0.47% 115
2020
Q3 		– Sell
-46,362
Closed -$186K – 278
2020
Q2 		$186K Sell
46,362
-33,558
-42% -$117K 0.03% 292
2020
Q1 		$203K Buy
79,920
+19,300
+32% +$63.4K 0.02% 256
2019
Q4 		$211K Buy
60,620
+20,056
+49% +$70.6K 0.02% 242
2019
Q3 		$188K Sell
40,564
-140,416
-78% -$1.11M 0.02% 257
2019
Q2 		$2.23M Sell
180,980
-7,228
-4% -$92.1K 0.17% 139
2019
Q1 		$2.5M Buy
+188,208
New +$1.98M 0.19% 132
2016
Q3 		– Sell
-40,696
Closed -$367K – 404
2016
Q2 		$367K Sell
40,696
-226,227
-85% -$2.13M 0.03% 337
2016
Q1 		$2.15M Buy
266,923
+2,710
+1% +$19.5K 0.14% 163
2015
Q4 		$2.86M Buy
264,213
+207,213
+364% +$2.03M 0.21% 144
2015
Q3 		$462K Buy
+57,000
New +$897K 0.03% 314

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bogle Investment Management's LAB Position: Q1 2021 in Review

Bogle Investment Management sold out of Standard BioTools (LAB) in Q1 2021, closing a stake of 49,200 shares — an estimated $295K sold.

Bogle Investment Management first reported a position in LAB in Q3 2015 and held it in 11 quarters. The position peaked at $2.86M in Q4 2015. 138 funds tracked by Wall St. Rank hold LAB as of Q1 2021.

  • Bogle Investment Management reported no remaining Standard BioTools position as of Q1 2021 after selling out during the quarter.
  • Bogle Investment Management sold 49,200 Standard BioTools shares in Q1 2021, an estimated $295K.
  • Bogle Investment Management first reported a position in Standard BioTools in Q3 2015 and held it in 11 quarters.
  • Bogle Investment Management's Standard BioTools position peaked at $2.86M in Q4 2015.
  • 138 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2021.

Based on Bogle Investment Management's 13F filing for Q1 2021.